Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters

FEBS Journal

Volumn 277, Issue 18, 2010, Pages 3699-3714

  Shen, Chen Hsiang ^a   Wang, Yuan Fang ^a   Kovalevsky, Andrey Y ^a   Harrison, Robert W ^a   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

aspartic protease; conformational change; enzyme inhibition; HIV AIDS; X ray crystallography

Indexed keywords

AMPRENAVIR; ASPARTIC PROTEINASE; PROTEINASE; SAQUINAVIR;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG DETERMINATION; DRUG INHIBITION; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

AMINO ACID SUBSTITUTION; CARBAMATES; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; MOLECULAR CONFORMATION; MUTATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SAQUINAVIR; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77956326486     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07771.x     Document Type: Article

References (62)

1. UNAIDS (2009) Report on the Global AIDS Epidemic. UNAIDS Publication Series. World Health Organization, Geneva.
2. Tozser J (2001) HIV inhibitors: problems and reality. Ann NY Acad Sci 946, 145 159.
3. Walker BD Burton DR (2008) Toward an AIDS vaccine. Science 320, 760 764.
4. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M et al. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569 571.
5. Gottlinger HG, Sodroski JG Haseltine WA (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 86, 5781 5785.
6. Louis JM, Ishima R, Torchia DA Weber IT (2007) HIV-1 protease: structure, dynamics, and inhibition. Adv Pharmacol 55, 261 298.
7. Weber IT, Kovalevsky AY Harrison RW (2007) Frontiers in Drug Design & Discovery, Vol. 3. Bentham Science Publishers, Oak Park, IL, USA, 45 62.
8. Kim EE, Baker CT, Dwyer MD, Murcko MA, Rao BG, Tung RD Navia MA (1995) Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 117, 1181 1182.
9. Williams GC Sinko PJ (1999) Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 39, 211 238.
10. Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R et al. (2005) Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J Med Chem 48, 1813 1822.
11. Krohn A, Redshaw S, Ritchie JC, Graves BJ Hatada MH (1991) Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem 34, 3340 3342.
12. Tie Y, Kovalevsky AY, Boross P, Wang YF, Ghosh AK, Tozser J, Harrison RW Weber IT (2007) Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. Proteins 67, 232 242.
13. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM Richman DD (2008) Update of the drug resistance mutations in HIV-1. Top HIV Med 16, 138 145.
14. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ Shafer RW (2003) Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 77, 4836 4847.
15. Liu F, Kovalevsky AY, Louis JM, Boross PI, Wang YF, Harrison RW Weber IT (2006) Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. J Mol Biol 358, 1191 1199.
16. Pazhanisamy S, Stuver CM, Cullinan AB, Margolin N, Rao BG Livingston DJ (1996) Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J Biol Chem 271, 17979 17985.
17. Liu F, Boross PI, Wang YF, Tozser J, Louis JM, Harrison RW Weber IT (2005) Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol 354, 789 800.
18. Liu F, Kovalevsky AY, Tie Y, Ghosh AK, Harrison RW Weber IT (2008) Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. J Mol Biol 381, 102 115.
19. Kovalevsky AY, Tie Y, Liu F, Boross PI, Wang YF, Leshchenko S, Ghosh AK, Harrison RW Weber IT (2006) Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem 49, 1379 1387.
20. Murphy MD, Marousek GI Chou S (2004) HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. J Clin Virol 30, 62 67.
21. Roberts NA, Craig JC Sheldon J (1998) Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 12, 453 460.
22. Hoffman NG, Schiffer CA Swanstrom R (2003) Covariation of amino acid positions in HIV-1 protease. Virology 314, 536 548.
23. Maguire M, Shortino D, Klein A, Harris W, Manohitharajah V, Tisdale M, Elston R, Yeo J, Randall S, Xu F et al. (2002) Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother 46, 731 738.
24. Ishima R, Louis JM Torchia DA (2001) Characterization of two hydrophobic methyl clusters in HIV-1 protease by NMR spin relaxation in solution. J Mol Biol 305, 515 521.
25. Mahalingam B, Wang YF, Boross PI, Tozser J, Louis JM, Harrison RW Weber IT (2004) Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur J Biochem 271, 1516 1524.
26. Anfinsen CB Richards FM (1995) Advances in Protein Chemistry, Vol. 47, Academic Press, New York.
27. Kellis JT Jr., Nyberg K, Sali D Fersht AR (1988) Contribution of hydrophobic interactions to protein stability. Nature 333, 784 786.
28. Fioravanti E, Vellieux FM, Amara P, Madern D Weik M (2007) Specific radiation damage to acidic residues and its relation to their chemical and structural environment. J Synchrotron Radiat 14, 84 91.
29. Vaguine AA, Richelle J Wodak SJ (1999) SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr D Biol Crystallogr 55, 191 205.
30. Kovalevsky AY, Liu F, Leshchenko S, Ghosh AK, Louis JM, Harrison RW Weber IT (2006) Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol 363, 161 173.
31. Ghosh AK, Gemma S, Baldridge A, Wang YF, Kovalevsky AY, Koh Y, Weber IT Mitsuya H (2008) Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. J Med Chem 51, 6021 6033.
32. Wang YF, Tie Y, Boross PI, Tozser J, Ghosh AK, Harrison RW Weber IT (2007) Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease. J Med Chem 50, 4509 4515.
33. Tie Y, Boross PI, Wang YF, Gaddis L, Liu F, Chen X, Tozser J, Harrison RW Weber IT (2005) Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J 272, 5265 5277.
34. Gustchina A, Sansom C, Prevost M, Richelle J, Wodak SY, Wlodawer A Weber IT (1994) Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures. Protein Eng 7, 309 317.
35. Spinelli S, Liu QZ, Alzari PM, Hirel PH Poljak RJ (1991) The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochimie 73, 1391 1396.
36. Foulkes JE, Prabu-Jeyabalan M, Cooper D, Henderson GJ, Harris J, Swanstrom R Schiffer CA (2006) Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol 80, 6906 6916.
37. Hong L, Zhang XC, Hartsuck JA Tang J (2000) Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci 9, 1898 1904.
38. Prabu-Jeyabalan M, Nalivaika E Schiffer CA (2000) How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease J Mol Biol 301, 1207 1220.
39. Short GF III., Laikhter AL, Lodder M, Shayo Y, Arslan T Hecht SM (2000) Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues. Biochemistry 39, 8768 8781.
40. Stebbins J, Towler EM, Tennant MG, Deckman IC Debouck C (1997) The 80's loop (residues 78 to 85) is important for the differential activity of retroviral proteases. J Mol Biol 267, 467 475.
41. Foulkes-Murzycki JE, Scott WR Schiffer CA (2007) Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure 15, 225 233.
42. Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW Weber IT (2004) High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 338, 341 352.
43. Mahalingam B, Boross P, Wang YF, Louis JM, Fischer CC, Tozser J, Harrison RW Weber IT (2002) Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins 48, 107 116.
44. Heaslet H, Kutilek V, Morris GM, Lin YC, Elder JH, Torbett BE Stout CD (2006) Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3. J Mol Biol 356, 967 981.
45. Martin P, Vickrey JF, Proteasa G, Jimenez YL, Wawrzak Z, Winters MA, Merigan TC Kovari LC (2005) "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 13, 1887 1895.
46. Saskova KG, Kozisek M, Rezacova P, Brynda J, Yashina T, Kagan RM Konvalinka J (2009) Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J Virol 83, 8810 8818.
47. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y et al. (2003) Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 47, 3123 3129.
48. Randolph JT DeGoey DA (2004) Peptidomimetic inhibitors of HIV protease. Curr Top Med Chem 4, 1079 1095.
49. Sayer JM, Liu F, Ishima R, Weber IT Louis JM (2008) Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem 283, 13459 13470.
50. Cigler P, Kozisek M, Rezacova P, Brynda J, Otwinowski Z, Pokorna J, Plesek J, Gruner B, Doleckova-Maresova L, Masa M et al. (2005) From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV protease. Proc Natl Acad Sci USA 102, 15394 15399.
51. Damm KL, Ung PM, Quintero JJ, Gestwicki JE Carlson HA (2008) A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket. Biopolymers 89, 643 652.
52. Wondrak EM Louis JM (1996) Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 35, 12957 12962.
53. Mahalingam B, Louis JM, Hung J, Harrison RW Weber IT (2001) Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43, 455 464.
54. Otwinowski Z Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 267, 307 326.
55. McCoy AJ, Grosse-Kunstleve RW, Storoni LC Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61, 458 464.
56. Vagin A Teplyakov A (1997) MOLREP: an automated program for molecular replacement. J Appl Crystallogr 30, 1022 1025.
57. Sheldrick GM Schneider TR (1997) SHELXL: high-resolution refinement. Methods Enzymol 277, 319 343.
58. Murshudov GN, Vagin AA Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240 255.
59. Dodson E (1996) Macromolecular Refinement: Proceedings of the CCP4 Study Weekend. CCLRC Daresbury Laboratory, Daresbury, UK.
60. Emsley P Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126 2132.
61. DeLano WL (2002) The PyMOL Molecular Graphics System. DeLano Scientific, San Carlos, CA.
62. Tie Y (2006) Crystallographic Analysis and Kinetic Studies of HIV-1 Protease and Drug-resistant Mutants. PhD, Georgia State University, Atlanta, GA.